Literature DB >> 19840254

Association between epidermal growth factor 61A/G polymorphism and hepatocellular carcinoma susceptibility in Chinese patients.

Yajuan Li1, Qing Xie, Fengmin Lu, Jingmin Zhao, Panyong Mao, Zhuo Li, Shuang Liu, Hui Zhuang.   

Abstract

BACKGROUND AND AIMS: Chronic hepatitis B virus (HBV) infection is an important risk factor for hepatocellular carcinoma (HCC) development in China, while little is known of the genetic susceptibility to hepatocarcinogenesis. The epidermal growth factor (EGF) pathway plays an important role in tumorigenesis, including HCC. EGF polymorphisms are associated with susceptibility to several types of cancers. Therefore, this study aimed to assess whether EGF genetic polymorphisms can influence HCC development.
METHODS: A total of 338 chronic HBV-infected patients (186 HCC patients and 152 cirrhotic patients) and 186 healthy individuals were enrolled in this study. EGF 61A/G polymorphisms of all subjects and 12 cell lines were assayed with polymerase chain reaction-restriction fragment length polymorphism and the sequencing method. Furthermore, EGF protein levels were measured in the serum and the results were compared with the different genotypes. EGF expression in the liver tissue of the HCC patients was detected by immunohistochemical analysis.
RESULTS: EGF 61A and 61G allele frequencies in healthy subjects were 28.76 and 71.24%. EGF 61GG and G allele frequencies in the HCC group were higher than those in the cirrhosis group. EGF protein levels with the GG genotype were significantly higher than those with either the GA or the AA genotype. About 59.09% of HCC liver tumour tissues assayed showed EGF protein expression.
CONCLUSIONS: The EGF 61 GG genotype might be associated with a high risk for the development of chronic HBV infection-related HCC in Chinese patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19840254     DOI: 10.1111/j.1478-3231.2009.02134.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  16 in total

1.  Quantitative assessment of the effect of epidermal growth factor 61A/G polymorphism on the risk of hepatocellular carcinoma.

Authors:  Xian-Feng Shen; Xian-Tao Zeng; Zhi-Yuan Jian; Meng Zhou; Ping Zhou; Min Zhang
Journal:  Oncol Lett       Date:  2015-09-18       Impact factor: 2.967

Review 2.  Molecular classification and novel targets in hepatocellular carcinoma: recent advancements.

Authors:  Yujin Hoshida; Sara Toffanin; Anja Lachenmayer; Augusto Villanueva; Beatriz Minguez; Josep M Llovet
Journal:  Semin Liver Dis       Date:  2010-02-19       Impact factor: 6.115

3.  A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma.

Authors:  Barham K Abu Dayyeh; May Yang; Bryan C Fuchs; Daniel L Karl; Suguru Yamada; John J Sninsky; Thomas R O'Brien; Jules L Dienstag; Kenneth K Tanabe; Raymond T Chung
Journal:  Gastroenterology       Date:  2011-03-24       Impact factor: 22.682

4.  Association between epidermal growth factor gene +61A/G polymorphism and the risk of hepatocellular carcinoma: a meta-analysis based on 16 studies.

Authors:  Guoping Jiang; Ke Yu; Lifang Shao; Xiaobo Yu; Chen Hu; Pei Qian; Haiyang Xie; Jinjun Li; Jie Zheng; Shusen Zheng
Journal:  BMC Cancer       Date:  2015-04-25       Impact factor: 4.430

5.  Association of epidermal growth factor and epidermal growth factor receptor polymorphisms with the risk of hepatitis B virus-related hepatocellular carcinoma in the population of North China.

Authors:  Jia Wu; Wei Zhang; Aiqiang Xu; Li Zhang; Tao Yan; Zhuo Li; Xiaopan Wu; Xilin Zhu; Juan Ma; Ke Li; Hui Li; Ying Liu
Journal:  Genet Test Mol Biomarkers       Date:  2013-06-22

6.  Carriage of the EGF rs4444903 A>G functional polymorphism associates with disease progression in chronic HBV infection.

Authors:  S Cmet; C Fabris; G Fattovich; E Falleti; D Bitetto; A Cussigh; E Fontanini; E Fornasiere; M Pirisi; P Toniutto
Journal:  Clin Exp Immunol       Date:  2012-02       Impact factor: 4.330

7.  Analysis of EGF+61A>G polymorphism and EGF serum levels in Brazilian glioma patients treated with perillyl alcohol-based therapy.

Authors:  Francisco das Chagas Abreu da Silveira; Bruno de Almeida Lopes; Clovis Orlando da Fonseca; Thereza Quirico-Santos; Izabel Christina Nunes de Palmer Paixão; Lidia Maria da Fonte de Amorim
Journal:  J Cancer Res Clin Oncol       Date:  2012-04-06       Impact factor: 4.553

8.  Association between EGF +61 G/A and glioma risk in a Chinese population.

Authors:  Shujie Wang; Yao Zhao; Zhenchao Ruan; Hongyan Chen; Weiwei Fan; Juxiang Chen; Qihan Wu; Ji Qian; Tianbao Zhang; Yan Huang; Daru Lu
Journal:  BMC Cancer       Date:  2010-05-21       Impact factor: 4.430

9.  Epidermal growth factor, its receptor and transforming growth factor-β1 in the diagnosis of HCV-induced hepatocellular carcinoma.

Authors:  Fatma Shehata; Nihad Abdel Monem; Mohamed Sakr; Samar Kasem; Mahmoud Balbaa
Journal:  Med Oncol       Date:  2013-08-03       Impact factor: 3.064

10.  Epidermal growth factor 61A>G polymorphism is associated with risk of hepatocellular carcinoma: a meta-analysis.

Authors:  Zhiping Yang; Qiong Wu; Yongquan Shi; Yongzhan Nie; Kaichun Wu; Daiming Fan
Journal:  Genet Test Mol Biomarkers       Date:  2012-08-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.